There were no major surprises in Celgene Corp.'s second quarter earnings, but the financial report did ease anxiety about Otezla (apremilast) – the first major product to help the company diversify its portfolio beyond the Revlimid (lenalidomide)-led hematology and oncology franchise.
Celgene Eases Angst Over Otezla, Sets The Stage For Growth
Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.
